Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · see citing works

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

Mdm2 promotes the rapid degradation of p53

Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · see citing works

The Bcl2 family: regulators of the cellular life-or-death switch

Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032 · see citing works

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · see citing works

Regulation of p53 stability by Mdm2

Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · see citing works

A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia

Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047 · see citing works

p53 is required for radiation-induced apoptosis in mouse thymocytes

Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864 · see citing works

The p53 pathway: positive and negative feedback loops

Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967 · see citing works

Transcriptional control of human p53-regulated genes

Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921 · see citing works

Bid, Bax, and Lipids Cooperate to Form Supramolecular Openings in the Outer Mitochondrial Membrane

Kuwana, T., Mackey, M. R., Perkins, G. A., Ellisman, M. H., Latterich, M., Schneiter, R., Green, D. R., & Newmeyer, D. D. (2002) · Cell · doi:10.1016/s0092-8674(02)01036-x · Cited by 1,480 · see citing works

Apoptosis - the p53 network

Haupt, S., Berger, M., Goldberg, Z., & Haupt, Y. (2003) · Journal of Cell Science · doi:10.1242/jcs.00739 · Cited by 1,136 · see citing works

Decision making by p53: life, death and cancer

Oren, M. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401183 · Cited by 1,063 · see citing works

Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2

Li, M., Brooks, C. L., Wu-Baer, F., Chen, D., Baer, R., & Gu, W. (2003) · Science · doi:10.1126/science.1091362 · Cited by 804 · see citing works

p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells.

Chen, X., Ko, L. J., Jayaraman, L., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.19.2438 · Cited by 735 · see citing works

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 723 · see citing works

Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening

McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658 · see citing works

Posttranslational Modification of p53: Cooperative Integrators of FunctionPreprint

Meek, D. W., & Anderson, C. W. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000950 · Cited by 487 · see citing works

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462 · see citing works

Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia

Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352 · see citing works

Two-phase dynamics of p53 in the DNA damage response

Zhang, X.-P., Liu, F., & Wang, W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100600108 · Cited by 333 · see citing works

SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression

Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0799 · Cited by 328 · see citing works

The p53-p21-DREAM-CDE/CHR pathway regulates G 2 /M cell cycle genes

Fischer, M., Quaas, M., Steiner, L., & Engeland, K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv927 · Cited by 324 · see citing works

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models

Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283 · see citing works

A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis.

Kracikova, M., Akiri, G., George, A., Sachidanandam, R., & Aaronson, S. A. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.155 · Cited by 261 · see citing works

The ups and downs of p53: understanding protein dynamics in single cells

Batchelor, E., Loewer, A., & Lahav, G. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2604 · Cited by 242 · see citing works

p53 regulation by ubiquitin

Brooks, C. L., & Gu, W. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.05.022 · Cited by 186 · see citing works

Limiting the power of p53 through the ubiquitin proteasome pathwayPreprint

Pant, V., & Lozano, G. (2014) · Genes & Development · doi:10.1101/gad.247452.114 · Cited by 165 · see citing works

Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation.

Yang, H. S., Filipovic, Z., Brown, D. A., Breit, S. N., & Vassilev, L. T. (2003) · PubMed · Cited by 157 · see citing works

The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents

Canon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0710 · Cited by 152 · see citing works

Ubiquitin-independent p53 proteasomal degradation

Tsvetkov, P., Reuven, N. B., & Shaul, Y. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.67 · Cited by 134 · see citing works

MDM2 and MDMX: Alone and together in regulation of p53.

Shadfan, M., Lopez-Pajares, V., & Yuan, Z.-M. (2012) · PubMed · Cited by 125 · see citing works

ATARiS: Computational quantification of gene suppression phenotypes from multisample RNAi screensPreprint

Shao, D. D., Tsherniak, A., Gopal, S., Weir, B., Tamayo, P., Stransky, N., Schumacher, S., Zack, T., Beroukhim, R., Garraway, L., et al. (2013) · Genome Research · doi:10.1101/gr.143586.112 · Cited by 124 · see citing works

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

Lehmann, C. H. K., Friess, T., Birzele, F., Kiialainen, A., & Dangl, M. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0280-3 · Cited by 106 · see citing works

p53 pulses lead to distinct patterns of gene expression albeit similar DNA-binding dynamics

Hafner, A., Stewart-Ornstein, J., Purvis, J. E., Forrester, W. C., Bulyk, M. L., & Lahav, G. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3452 · Cited by 94 · see citing works

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Jeay, S., Gaulis, S., Ferretti, S., Bitter, H., Ito, M., Valat, T., Murakami, M., Ruetz, S., Guthy, D. A., Rynn, C., et al. (2015) · eLife · doi:10.7554/elife.06498 · Cited by 85 · see citing works

Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

Furet, P., Masuya, K., Kallen, J., Stachyra-Valat, T., Ruetz, S., Guagnano, V., Holzer, P., Mah, R., Stutz, S., Vaupel, A., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.010 · Cited by 80 · see citing works

The central valine concept provides an entry in a new class of non peptide inhibitors of the p53–MDM2 interaction

Furet, P., Chêne, P., Pover, A. D., Stachyra, T., Lisztwan, J. H., Kallen, J. A., & Masuya, K. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.03.083 · Cited by 73 · see citing works

The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo

Kuribayashi, K., Finnberg, N. K., Jeffers, J. R., Zambetti, G. P., & El‐Deiry, W. S. (2011) · Cell Cycle · doi:10.4161/cc.10.14.16588 · Cited by 69 · see citing works

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf ^−/− mouse model

Chapeau, E. A., Gembarska, A., Durand, E. Y., Mandon, E., Estadieu, C., Romanet, V., Wiesmann, M., Tiedt, R., Lehar, J., de Weck, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620262114 · Cited by 64 · see citing works

Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach

Higgins, B., Glenn, K., Walz, A., Tovar, C., Filipovic, Z., Hussain, S., Lee, E., Kolinsky, K., Tannu, S., Adames, V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0460 · Cited by 63 · see citing works

Transcriptional Regulation of thep53Tumor Suppressor Gene in S-Phase of the Cell-Cycle and the Cellular Response to DNA Damage

Reisman, D., Takahashi, P., Polson, A., & Boggs, K. (2012) · Biochemistry Research International · doi:10.1155/2012/808934 · Cited by 60 · see citing works

Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia <i>In Vitro</i> and <i>In Vivo</i>

Hoffman-Luca, C. G., Ziazadeh, D., McEachern, D., Zhao, Y., Sun, W., Debussche, L., & Wang, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2506 · Cited by 52 · see citing works

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells

Carter, B. Z., Mak, P. Y., Mak, D. H. F., Ruvolo, V. R., Schober, W. D., McQueen, T. J., Cortes, J. E., Kantarjian, H. M., Champlin, R. E., Konopleva, M. Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5890 · Cited by 44 · see citing works

Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737

Gu, D., Wang, S., Kuiatse, I., Wang, H., He, J., Dai, Y., Jones, R. J., Bjorklund, C. C., Yang, J., Grant, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103015 · Cited by 34 · see citing works

Dose- and regimen-finding phase I study of NVP-HDM201 in patients (pts) with TP53 wild-type (wt) advanced tumors

Hyman, D. M., Chatterjee, M., Langenberg, M. H. G., Lin, C. C., Suárez, C., Tai, D., Cassier, P. A., YAMAMOTO, N., de Weger, V. A., Jeay, S., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32982-3 · Cited by 15 · see citing works

Drugging p53 in cancer: one protein, many targets

Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 736 · see citing works

Targeting mutant p53 for cancer therapy: direct and indirect strategies

Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 557 · see citing works

p21 in Cancer Research

Shamloo, B., & Usluer, S. (2019) · Cancers · doi:10.3390/cancers11081178 · Cited by 336 · see citing works

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

Zhu, H., Gao, H., Ji, Y., Zhou, Q., Du, Z., Tian, L., Jiang, Y., Yao, K., & Zhou, Z. (2022) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-022-01314-3 · Cited by 223 · see citing works

Targeting pan-essential genes in cancer: Challenges and opportunities

Chang, L., Ruiz, P. A., Ito, T., & Sellers, W. R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.008 · Cited by 183 · see citing works

MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

Wang, W., Albadari, N. G., Du, Y., Fowler, J. F., Sang, H. T., Xian, W., McKeon, F., Li, W., Zhou, J., & Zhang, R. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001026 · Cited by 147 · see citing works

The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy

Liu, Y., Wang, X., Wang, G., Yang, Y., Yuan, Y., & Ouyang, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.018 · Cited by 133 · see citing works

The role of TP53 in acute myeloid leukemia: Challenges and opportunities

Barbosa, K., Li, S., Adams, P. D., & Deshpande, A. J. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22796 · Cited by 115 · see citing works

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia

Stein, E. M., DeAngelo, D. J., Chromik, J., Chatterjee, M., Bauer, S., Lin, C.-C., Suárez, C., Vos, F. D., Steeghs, N., Cassier, P. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1295 · Cited by 88 · see citing works

Unraveling the Guardian: p53’s Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies

Zhang, H., Xu, J., Long, Y., Maimaitijiang, A., Su, Z., Li, W., & Li, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312928 · Cited by 93 · see citing works

Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors

LaPlante, G., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers13123079 · Cited by 82 · see citing works

The relationship between TRAF6 and tumors

Li, J., Liu, N., Tang, L. Y., Yan, B., Chen, X., Zhang, J., & Peng, C. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01517-z · Cited by 72 · see citing works

Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study

Razak, A. R. A., Bauer, S., Suárez, C., Lin, C., Quek, R. H. H., Hütter‐Krönke, M. L., Cubedo, R., Ferretti, S., Guerreiro, N., Jullion, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1291 · Cited by 70 · see citing works

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?

Hároníková, L., Bonczek, O., Zatloukalová, P., Kokas, F. Z., Kucerikova, M., Coates, P. J., Fåhræus, R., & Vojtěšek, B. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00293-6 · Cited by 71 · see citing works

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

Portman, N., Milioli, H. H., Alexandrou, S., Coulson, R. S., Yong, A., Fernandez, K. J., Chia, K. M., Halilovic, E., Segara, D., Parker, A., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01318-2 · Cited by 65 · see citing works

Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study

Takahashi, S., Fujiwara, Y., Nakano, K., Shimizu, T., Tomomatsu, J., Koyama, T., Ogura, M., Tachibana, M., Kakurai, Y., Yamashita, T., et al. (2021) · Cancer Science · doi:10.1111/cas.14875 · Cited by 60 · see citing works

Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment

Wang, H. Q., Mulford, I. J., Sharp, F. A., Liang, J., Kurtuluş, S., Trabucco, G. M., Quinn, D. S., Longmire, T. A., Patel, N., Patil, R. A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-0189 · Cited by 60 · see citing works

Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma

Traweek, R. S., Cope, B. M., Roland, C. L., Keung, E. Z.-Y., Nassif, E. F., & Erstad, D. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1006959 · Cited by 61 · see citing works

MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models

Fang, D. D., Tang, Q., Kong, Y., Rong, T., Wang, Q., Li, N., Fang, X., Gu, J., Xiong, D., Yin, Y., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00465-5 · Cited by 58 · see citing works

Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein–Protein Interactions

Zhang, S., Lou, J., Li, Y., Zhou, F., Yan, Z., Lyu, X., & Zhao, Y. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00940 · Cited by 47 · see citing works

Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Koyama, T., Shimizu, T., Kojima, Y., Sudo, K., Okuma, H. S., Shimoi, T., Ichikawa, H., Kohsaka, S., Sadachi, R., Hirakawa, A., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0419 · Cited by 46 · see citing works

Chalcones as Promising Antitumor Agents by Targeting the p53 Pathway: An Overview and New Insights in Drug-Likeness

Moreira, J., Almeida, J., Saraiva, L., Cidade, H. M., & Pinto, M. M. M. (2021) · Molecules · doi:10.3390/molecules26123737 · Cited by 41 · see citing works

p53 enhances DNA repair and suppresses cytoplasmic chromatin fragments and inflammation in senescent cells

Miller, K. N., Li, B., Pierce-Hoffman, H. R., Patel, S., Lei, X., Rajesh, A., Teneche, M. G., Havas, A. P., Gandhi, A., Macip, C. C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57229-3 · Cited by 41 · see citing works

Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer

Li, W., Peng, X., Lang, J., & Xu, C. S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00631 · Cited by 36 · see citing works

Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies

Bauer, S., Demetri, G. D., Halilovic, E., Dummer, R., Meille, C., Tan, D. S.-W., Guerreiro, N., Jullion, A., Ferretti, S., Jeay, S., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01444-4 · Cited by 37 · see citing works

p53 as a potential target for treatment of cancer: A perspective on recent advancements in small molecules with structural insights and SAR studies

Chahat, Bhatia, R., & Kumar, B. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115020 · Cited by 36 · see citing works

BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models

Hao, X., Bahia, R. K., Cseh, O., Bozek, D. A., Blake, S., Rinnenthal, J., Weyer-Czernilofsky, U., Rudolph, D., & Artee Luchman, H. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac271 · Cited by 34 · see citing works

Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens

Alaseem, A. M. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101790 · Cited by 36 · see citing works

MDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation

Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023) · Biomedicines · doi:10.3390/biomedicines11071879 · Cited by 30 · see citing works

Structural States of Hdm2 and HdmX: X‐ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes

Kallen, J. A., Izaac, A., Chau, S., Wirth, E., Schoepfer, J. G., Mah, R., Schlapbach, A., Stutz, S., Vaupel, A., Guagnano, V., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900201 · Cited by 30 · see citing works

MDM2 phosphorylation mediates H2O2-induced lens epithelial cells apoptosis and age-related cataract

Wang, Z., Su, D., Sun, Z., Liu, S., Sun, L., Li, Q., Guan, L., Liu, Y. U., Ma, X., & Hu, S. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.05.060 · Cited by 28 · see citing works

Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy

Sun, D., Qian, H., Li, J., & Xing, P. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01004-x · Cited by 27 · see citing works

Therapeutic Strategies to Activate p53

Aguilar, A., & Wang, S. (2022) · Pharmaceuticals · doi:10.3390/ph16010024 · Cited by 27 · see citing works

MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)

Rusiecki, R., Witkowski, J., & Jaszczewska‐Adamczak, J. A. (2019) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892814666191022163540 · Cited by 27 · see citing works

Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy

Olaoba, O. T., Adelusi, T. I., Yang, M. J., Maidens, T., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2024) · Cancers · doi:10.3390/cancers16101808 · Cited by 26 · see citing works

KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors

Chutake, Y. K., Mayo, M., Dumont, N., Filiatrault, J., Breitkopf, S. B., Cho, P., Chen, D., Dixit, V. S., Proctor, W. R., Kuhn, E. W., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0306 · Cited by 26 · see citing works

Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201

Guerreiro, N., Jullion, A., Ferretti, S., Fabre, C., & Meille, C. (2021) · The AAPS Journal · doi:10.1208/s12248-020-00551-z · Cited by 22 · see citing works

In Vitro Characterization of a Potent p53-MDM2 Inhibitor, RG7112 in Neuroblastoma Cancer Cell Lines

Al‐Ghabkari, A., & Narendran, A. (2019) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2018.2732 · Cited by 22 · see citing works

Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2/MdmX Interaction

Huang, Y., Wang, L., Zhou, Y., Bai, J., Li, N., Su, Z., & Cheng, X. (2025) · Cells · doi:10.3390/cells14080583 · Cited by 23 · see citing works

Prognostic Score Predicts Survival in HPV-Negative Head and Neck Squamous Cell Cancer Patients

Qian, X., Nguyen, D. T., Dong, Y., Sinikovic, B., Kaufmann, A. M., Myers, J. N., Albers, A. E., & Graviss, E. A. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.33329 · Cited by 21 · see citing works

Absolute Binding Free Energy Calculations for Highly Flexible Protein MDM2 and Its Inhibitors

Singh, N., & Li, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134765 · Cited by 21 · see citing works

Tumor Microenvironment‐Responsive Polymer‐Based RNA Delivery Systems for Cancer Treatment

Zhang, Y., Zhang, M., Song, H., Dai, Q., & Liu, C. (2024) · Small Methods · doi:10.1002/smtd.202400278 · Cited by 20 · see citing works

A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma

Rendo, V., Lee, E. Q., Bossi, C., Khuu, N., Rudek, M. A., Pal, S., Azazmeh, N., Rashid, R., Lin, J.-R., Cusick, M., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adn6274 · Cited by 19 · see citing works

Structure and function of MDM2 and MDM4 in health and disease

Zhu, I. Y., Lloyd, A., Critchley, W. R., Saikia, Q., Jade, D., Divan, A., Zeqiraj, E., Harrison, M. A., Brown, C. J., & Ponnambalam, S. (2025) · Biochemical Journal · doi:10.1042/bcj20240757 · Cited by 21 · see citing works

Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery

Kono, M., Kumai, T., Hayashi, R., Yamaki, H., Komatsuda, H., Wakisaka, R., Nagato, T., Ohkuri, T., Kosaka, A., Ohara, K., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02940-5 · Cited by 19 · see citing works

Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia

Seipel, K., Schmitter, K., Bacher, U., & Pabst, T. (2019) · Cancers · doi:10.3390/cancers11111779 · Cited by 19 · see citing works

Potency and Selectivity Optimization of Tryptophanol‐Derived Oxazoloisoindolinones: Novel p53 Activators in Human Colorectal Cancer

Barcherini, V., Almeida, J., Lopes, E. A., Wang, M., Silva, D., Mori, M., Wang, S., Saraiva, L., & Santos, M. M. M. (2020) · ChemMedChem · doi:10.1002/cmdc.202000522 · Cited by 17 · see citing works

Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer

Montagut, A. M., Armengol, M., Gorjón-de-Pablo, G., Estrada‐Tejedor, R., Borrell, J. I., & Roué, G. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.02.007 · Cited by 17 · see citing works

Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma

Bevill, S. M., Casaní-Galdón, S., Farran, C. E. E., Cytrynbaum, E. G., Macias, K. A., Oldeman, S. E., Oliveira, K. J., Moore, M. M., Hegazi, E., Adriaens, C., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100321 · Cited by 17 · see citing works

Discovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia

Aguilar, A., Yang, J., Li, Y., McEachern, D., Huang, L., Razzouk, S., & Wang, S. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01818 · Cited by 16 · see citing works

Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma

Ananthapadmanabhan, V., Frost, T. C., Soroko, K. M., Knott, A., Magliozzi, B., Gokhale, P. C., Tirunagaru, V. G., Doebele, R. C., & DeCaprio, J. A. (2022) · JCI Insight · doi:10.1172/jci.insight.160513 · Cited by 15 · see citing works

MDM2 Implications for Potential Molecular Pathogenic Therapies of Soft-Tissue Tumors

Sun, S. Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113638 · Cited by 12 · see citing works

Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors

Si, D., Luo, H., Zhang, X., Yang, K., Wen, H., Li, J., & Li, J. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105268 · Cited by 12 · see citing works

Perspectives on drug discovery strategies based on IDPs

Fuertes, G., Nevola, L., & Esteban-Martín, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816348-1.00009-0 · Cited by 11 · see citing works

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I

Witkowski, J., Polak, S., Rogulski, Z., & Pawelec, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112984 · Cited by 9 · see citing works

Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies

Giercuszkiewicz-Haśnik, K., MORAK-MŁODAWSKA, B. I., & Jeleń, M. (2026) · Molecules · doi:10.3390/molecules31071195 · Cited by 11 · see citing works

Targets in MPNs and potential therapeutics

Levy, G., Mambet, C., Pecquet, C., Bailly, S., Havelange, V., Diaconu, C. C., & Constantinescu, S. N. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2021.06.004 · Cited by 9 · see citing works

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part II

Witkowski, J., Polak, S., Rogulski, Z., & Pawelec, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911939 · Cited by 8 · see citing works

New targeted treatments for advanced sarcomas

Li, C., & Chen, T. W. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000955 · Cited by 7 · see citing works

SNPs Give LACTB Oncogene‐Like Functions and Prompt Tumor Progression via Dual‐Regulating p53

Huang, G., Zhang, J., Xu, Y., Wu, F. L., Fu, Y., Zhang, X., Yin, H., You, Y., Zhao, P., Liu, W., et al. (2024) · Advanced Science · doi:10.1002/advs.202405907 · Cited by 7 · see citing works

Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation

Márquez-Cantudo, L., Ramos, A., Coderch, C., & de Pascual‐Teresa, B. (2021) · Molecules · doi:10.3390/molecules26185606 · Cited by 7 · see citing works

MDM2 inhibitors in sarcomas: results and next steps

Tortorelli, I., Napolitano, A., Zhou, Y., Huang, P. H., & Jones, R. L. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001146 · Cited by 7 · see citing works

A concise review on MDM2 inhibitors and recent progress in radiopharmaceutical development for imaging MDM2 expression in tumors with PET or SPECT

Siriki, A., Ragland, G., Vasireddy, J., & Chitneni, S. K. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130394 · Cited by 6 · see citing works

Targeting MDM2 for the development of a new cancer therapy: progress and challenges

Aguilar, A., Thomas, J. E., & Wang, S. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03102-1 · Cited by 6 · see citing works

Revealing binding selectivity of ligands toward murine double minute 2 and murine double minute X based on molecular dynamics simulations and binding free energy calculations

Shi, S., Sui, K., Liu, W., Lei, Y., Zhang, S., & Zhang, Q. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1695671 · Cited by 6 · see citing works

Expression and Clinical Significance of MDM2 in Non-Functioning PitNETs

Yao, X., Liu, Q., Zhao, S., Cheng, R., Liu, C., & Zhang, G. (2023) · Medicina · doi:10.3390/medicina59020373 · Cited by 4 · see citing works

TRAF6 Inhibitors from Marine Compound Library: Pharmacophore, Virtual Screening, Fragment Replacement, ADMET, and Molecular Dynamics

Wu, X., Zhong, S., Zhou, N., & Luo, L. (2024) · Marine Drugs · doi:10.3390/md22060260 · Cited by 4 · see citing works

BRAF V600E-induced distinct DNA damage response defines the therapeutic potential of p53 activation for TP53 wild-type colorectal cancer

Tokuyama, S., Kato, H., Takahashi, H., Ueda, K., Arita, A., Ueda, R., Seto, H., Sekido, Y., Hata, T., Hamabe, A., et al. (2024) · Carcinogenesis · doi:10.1093/carcin/bgae040 · Cited by 4 · see citing works

ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis

Ross, D. M., Heidel, F. H., Perkins, A. C., Reiter, A., Crodel, C. C., Riley, C. H., Gómez‐Casares, M. T., Takács, I., Becker, H., Lehmann, T., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025015860 · Cited by 3 · see citing works

Primary dedifferentiated liposarcoma of the gallbladder: a case report and literature review

Wang, L., Lin, T., Hai, Y., Yu, K., Bu, F., Lu, J., Wang, X., Li, M., & Shi, X. (2024) · Frontiers in Surgery · doi:10.3389/fsurg.2024.1452144 · Cited by 3 · see citing works

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III

Witkowski, J., Polak, S., Pawelec, D., & Rogulski, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032239 · Cited by 3 · see citing works

Discovery of Furopyrimidine‐Pyrazole Hybrid Compounds Targeting p53‐MDM2 Interaction as Anticancer Agents

Mansour, M. A., Hassan, G. S., Jaballah, M. Y., Serya, R. A. T., Dege, N., Şahın, O., Sharaky, M. M., Zhang, X., Su, R., De, K., et al. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70085 · Cited by 2 · see citing works

Detection of TP53 Mutation in Acute Myeloid Leukemia by RT-PCR-Based Sanger Sequencing

Novak, E. R., Deshpande, A. J., Finlay, D., Mason, J. R., Deshpande, A. J., Adams, P. D., & Li, S. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2815-7_7 · Cited by 2 · see citing works

Selection of prostate cancer therapy strategy under early androgen suppression treatment

Yao, M., Zhang, Y., & Wang, W. (2024) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2024.107914 · Cited by 1 · see citing works

Recent Advancements on the Anti-Tumor Small Molecule Inhibitors Targeting the p53-MDM2 Interaction

丁, 涵. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1381881 · Cited by 1 · see citing works

Dedifferentiated liposarcoma of the spermatic cord

Panther, E. J., Lyons, H., & Shychuk, A. J. (2024) · BMJ Case Reports · doi:10.1136/bcr-2023-258954 · Cited by 1 · see citing works

A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1)

Zhang, L., Poland, B., GREEN, M. L., Wong, S. L., & Slatter, J. G. (2022) · Xenobiotica · doi:10.1080/00498254.2022.2114116 · Cited by 1 · see citing works

Linked regulation of genome integrity and senescence-associated inflammation by p53Preprint

Miller, K. N., Li, B., Pierce-Hoffman, H. R., Patel, S., Lei, X., Rajesh, A., Teneche, M. G., Havas, A. P., Gandhi, A., Macip, C. C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.20.567963 · Cited by 1 · see citing works

Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts

Vaubel, R. A., Zhang, W., Karbhari, N., Oh, J.-H., Waller, K. L., Mladek, A., Jain, S., Burgenske, D. M., Decker, P. A., Kosel, M. L., et al. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf259

Deciphering mechanisms of response and resistance in large-scale mouse cancer screens

Prahallad, A., Jensen, M. R., & Chapeau, E. A. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.02.006

Data from Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study

Razak, A. R. A., Bauer, S., Suárez, C., Lin, C., Quek, R. H. H., Hütter‐Krönke, M. L., Cubedo, R., Ferretti, S., Guerreiro, N., Jullion, A., et al. (2023) · doi:10.1158/1078-0432.c.6530853

Data from Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment

Wang, H. Q., Mulford, I. J., Sharp, F. A., Liang, J., Kurtuluş, S., Trabucco, G. M., Quinn, D. S., Longmire, T. A., Patel, N., Patil, R. A., et al. (2023) · doi:10.1158/0008-5472.c.6513468.v1

Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastomaPreprint

Rendo, V., Lee, E. Q., Bossi, C. C., Khuu, N., Rudek, M. A., Pal, S., Reynolds, A. R. N., Fassinou, A. C. R., Ayoub, G., Lapinskas, E., et al. (2024) · medRxiv · doi:10.1101/2024.08.12.24311893

Combined inhibition of MDM2 and PARP lead to a synergistic anti-tumoral response in p53 wild-type rhabdomyosarcoma modelsPreprint

Pons, G., Zarzosa, P., Gallo-Oller, G., Wenz, A. S., Lapins, M., García-Gilabert, L., Sansa-Girona, J., Navarro, N., Segura, M. F., Soriano, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.03.626050

Protein-protein interaction inhibitors in cancer

Hardcastle, I. R., Goujon-Ricci, J., & Thompson, W. I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00067-4

Navigating the p53‐MDM2 Landscape: Molecular Insights and Therapeutic Strategies

Mansour, M. A., Hassan, G. S., & Abouzid, K. A. M. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70264

The influence of the secretome from human amniotic mesenchymal stem cells on p53 and MDM2 expression in MDA-MB-231 breast cancer cell line

Asadi, R., & Safari, F. (2026) · Discover Oncology · doi:10.1007/s12672-026-05412-3

BindingDB Entry 50007839: The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.

BindingDB (2021) · UC San Diego · doi:10.7270/q2v12851

BindingDB Entry 50018099: Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein-Protein Interactions.

BindingDB (2024) · UC San Diego · doi:10.7270/q2dv1q2x

Abstract 1224: Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials

Ferretti, S., Rebmann, R., Berger, M., Santacroce, F., Albrecht, G., Pollehn, K., Sterker, D., Wartmann, M., Hueber, A., Wiesmann, M., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-1224 · Cited by 10 · see citing works

Abstract 1225: NVP-HDM201: cellular and in vivo profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2

Jeay, S., Chêne, P., Ferretti, S., Furet, P., Gruenenfelder, B., Guagnano, V., Guerreiro, N., Halilovic, E., Hofmann, F., Kallen, J. A., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-1225 · Cited by 5 · see citing works

Abstract 4855: Discovery of NVP-HDM201 - First disclosure of a Next-Generation Mdm2 inhibitor with superior characteristics

Holzer, P., Chêne, P., Ferretti, S., Furet, P., Gabriel, T., Gruenenfelder, B., Guagnano, V., Hofmann, F., Kallen, J. A., Mah, R., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-4855 · Cited by 8 · see citing works

Study of the cytotoxic effect of a peptidic inhibitor of the p53–hdm2 interaction in tumor cells

Chêne, P., Fuchs, J. P., Carena, I., Furet, P., & Echeverrı́a, C. G. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03362-8 · Cited by 39 · see citing works

P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS.

Schalm, S. S., Chutake, Y. K., Breitkopf, S. B., Mayo, M., Dumont, N., Chen, D., Dixit, V. S., Karnik, R., McDonald, A. A., Filiatrault, J., et al. (2023) · HemaSphere · doi:10.1097/01.hs9.0000968764.90228.92 · Cited by 1 · see citing works